Latest News in the pharma Industry
Research & Development
Novartis and MMV launch patient trial in Africa for a novel compound against multidrug-resistant malaria
23 Aug 2017
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission.
Read more
Champions Oncology collaborates with AstraZeneca to develop unique cohorts of PDX models
21 Aug 2017
Models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer.
Read more
BMS and Pfizer to highlight commitment to reducing the risk of stroke at ECS Congress 2017
20 Aug 2017
Eliquis clinical data include results from a Phase IV trial to be featured in late-breaking science sessions,
Read more
A plant-based delivery system for anti-cancer drugs
20 Aug 2017
Study demonstrates that a complex consisting of tobacco mosaic virus and vcMMAE can kill cancer cells.
Read more
Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity
16 Aug 2017
Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.
Read more
Regeneron to discontinue development of suptavumab for respiratory syncytial virus
14 Aug 2017
Phase III study fails to meet its primary endpoint.
Read more
Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline
14 Aug 2017
Inotersen on track for marketing authorization filings this year.
Read more
Fortress Biotech forms new subsidiary, Aevitas Therapeutics
14 Aug 2017
Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.
Read more
Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD
14 Aug 2017
The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.
Read more
FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial
14 Aug 2017
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
Read more
Experimental treatment for Niemann-Pick disease type C1 appears safe, effective
13 Aug 2017
NIH-led clinical trial suggests that drug slows progression of rare neurological disease.
Read more
Major progress in next generation medicines initiative
10 Aug 2017
Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.
Read more